China Biotech Services Holdings Limited provided unaudited consolidated earnings guidance for the six months ended 30 June 2020. The Group is expected to record a net loss of not less than 45,000,000 for the 2020 Interim Period as compared to the net loss of approximately HKD 36,318,000 recorded for the corresponding period in 2019.